Aidan Hollis
Aidan Hollis
Professor of Economics, University of Calgary
Verified email at ucalgary.ca - Homepage
Title
Cited by
Cited by
Year
Microcredit: What can we learn from the past?
A Hollis, A Sweetman
World Development 26 (10), 1875-1891, 1998
2991998
Co-authorship and the output of academic economists
A Hollis
Labour economics 8 (4), 503-530, 2001
2162001
The Health Impact Fund: Making New Medicines Accessible for All: a Report of Incentives for Global Health
A Hollis, TWM Pogge, Incentives for Global Health
Incentives for Global Health, 2008
1972008
Preserving antibiotics, rationally
A Hollis, Z Ahmed
New England Journal of Medicine 369 (26), 2474-2476, 2013
1682013
An economic justification for open access to essential medicine patents in developing countries
S Flynn, A Hollis, M Palmedo
The Journal of Law, Medicine & Ethics 37 (2), 184-208, 2009
1482009
The importance of being first: evidence from Canadian generic pharmaceuticals
A Hollis
Health Economics 11 (8), 723-734, 2002
1142002
The large-scale integration of wind generation: Impacts on price, reliability and dispatchable conventional suppliers
J MacCormack, A Hollis, H Zareipour, W Rosehart
Energy policy 38 (7), 3837-3846, 2010
1032010
A contractual approach to the gray market
NT Gallini, A Hollis
International Review of Law and Economics 19 (1), 1-21, 1999
1021999
The life-cycle of a microfinance institution: The Irish loan funds
A Hollis, A Sweetman
Journal of Economic Behavior & Organization 46 (3), 291-311, 2001
982001
The anti-competitive effects of brand-controlled" pseudo-generics" in the Canadian pharmaceutical market
A Hollis
Canadian Public Policy/Analyse de Politiques, 21-32, 2003
852003
The Health Impact Fund: incentives for improving access to medicines
A Banerjee, A Hollis, T Pogge
Lancet (London, England) 12 (9709), 2010
822010
An efficient reward system for pharmaceutical innovation
A Hollis
Retrieved Dec 9, 2004
822004
Microcredit in prefamine Ireland
A Hollis, A Sweetman
Explorations in Economic History 35 (4), 347-380, 1998
761998
The Health Impact Fund: boosting pharmaceutical innovation without obstructing free access
T Pogge
Cambridge Q. Healthcare Ethics 18, 78, 2009
60*2009
Extended warranties, adverse selection, and aftermarkets
A Hollis
Journal of Risk and Insurance, 321-343, 1999
601999
Microfinance and famine: the Irish loan funds during the great famine
A Hollis, A Sweetman
World Development 32 (9), 1509-1523, 2004
542004
How do brands’“own generics” affect pharmaceutical prices?
A Hollis
Review of Industrial Organization 27 (4), 329-350, 2005
522005
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
K Jayasundara, A Hollis, M Krahn, M Mamdani, JS Hoch, P Grootendorst
Orphanet journal of rare diseases 14 (1), 1-10, 2019
462019
Me-too drugs: is there a problem
A Hollis
WHO report, 2004
462004
Antibiotic resistance is a tragedy of the commons that necessitates global cooperation
A Hollis, P Maybarduk
The Journal of Law, Medicine & Ethics 43 (3_suppl), 33-37, 2015
412015
The system can't perform the operation now. Try again later.
Articles 1–20